Literature DB >> 9670842

Elevated serum levels of IFN-gamma, IL-4 and TNF-alpha/unelevated serum levels of IL-10 in patients with demyelinating diseases during the acute stage.

K Hohnoki1, A Inoue, C S Koh.   

Abstract

We investigated IFN-gamma, IL-4, IL-10 and TNF-alpha in the sera of 42 patients with demyelinating diseases: multiple sclerosis (MS) (21), Guillain-Barré syndrome (GBS) (14), Miller-Fisher syndrome (MFS) (7) during the acute or active stage and 12 normal controls using an originally devised sensitive sandwich enzyme-linked immunosorbent assay (ELISA). We found elevated serum levels of IFN-gamma derived from T helper 1 (Th1) cells and of IL-4 derived from Th2 cells in MS, GBS and MFS. It has been reported in several studies that IL-4 production is increased in MS; however, there have been no reports of elevated serum IL-4 levels in MS. We here describe elevated serum levels of IL-4 in MS, GBS and MFS for the first time. Serum TNF-alpha levels were significantly elevated in patients with MS (p < 0.01). Serum TNF-alpha levels also tended to be elevated in patients with GBS and MFS, but not significantly elevated compared with those of controls. Serum IL-10 levels were not elevated significantly in these diseases, although several patients had higher levels of serum IL-10 than controls. These findings suggest that simultaneous activation of both Th1 and Th2 cells may occur during the acute stage, indicating systemic involvement of the immune system in patients with MS, GBS and MFS. Levels of serum IFN-gamma were two- to three-fold higher than those of serum IL-4 in all three demyelinating diseases. We may then conclude that Th1 response may be dominant in GBS and MFS during the acute stage.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9670842     DOI: 10.1016/s0165-5728(98)00053-8

Source DB:  PubMed          Journal:  J Neuroimmunol        ISSN: 0165-5728            Impact factor:   3.478


  29 in total

Review 1.  T cell subsets and their signature cytokines in autoimmune and inflammatory diseases.

Authors:  Itay Raphael; Saisha Nalawade; Todd N Eagar; Thomas G Forsthuber
Journal:  Cytokine       Date:  2014-10-30       Impact factor: 3.861

Review 2.  A review of the role of genetic factors in Guillain-Barré syndrome.

Authors:  Amin Safa; Tahereh Azimi; Arezou Sayad; Mohammad Taheri; Soudeh Ghafouri-Fard
Journal:  J Mol Neurosci       Date:  2020-10-07       Impact factor: 3.444

3.  T cell reactivity to P0, P2, PMP-22, and myelin basic protein in patients with Guillain-Barre syndrome and chronic inflammatory demyelinating polyradiculoneuropathy.

Authors:  P A Csurhes; A-A Sullivan; K Green; M P Pender; P A McCombe
Journal:  J Neurol Neurosurg Psychiatry       Date:  2005-10       Impact factor: 10.154

Review 4.  The paradigm of Th1 and Th2 cytokines: its relevance to autoimmunity and allergy.

Authors:  V K Singh; S Mehrotra; S S Agarwal
Journal:  Immunol Res       Date:  1999       Impact factor: 2.829

5.  Interleukin-33 upregulation in peripheral leukocytes and CNS of multiple sclerosis patients.

Authors:  George P Christophi; Ross C Gruber; Michael Panos; Rebecca L Christophi; Burk Jubelt; Paul T Massa
Journal:  Clin Immunol       Date:  2011-12-02       Impact factor: 3.969

6.  Quantitative differences in the immunomodulatory effects of Rebif and Avonex in IFN-β 1a treated multiple sclerosis patients.

Authors:  George P Christophi; Jennifer A Christophi; Ross C Gruber; Cornelia Mihai; Luis J Mejico; Paul T Massa; Burk Jubelt
Journal:  J Neurol Sci       Date:  2011-06-11       Impact factor: 3.181

Review 7.  The role of cytokines in Guillain-Barré syndrome.

Authors:  Ming-Ou Lu; Jie Zhu
Journal:  J Neurol       Date:  2010-11-23       Impact factor: 4.849

8.  T helper cell type 1 (Th1), Th2 and Th17 responses to myelin basic protein and disease activity in multiple sclerosis.

Authors:  Chris J Hedegaard; Martin Krakauer; Klaus Bendtzen; Henrik Lund; Finn Sellebjerg; Claus H Nielsen
Journal:  Immunology       Date:  2008-04-04       Impact factor: 7.397

9.  Interferon-beta treatment in multiple sclerosis attenuates inflammatory gene expression through inducible activity of the phosphatase SHP-1.

Authors:  George P Christophi; Michael Panos; Chad A Hudson; Chriso Tsikkou; Cornelia Mihai; Luis J Mejico; Burk Jubelt; Paul T Massa
Journal:  Clin Immunol       Date:  2009-06-25       Impact factor: 3.969

10.  Macrophages of multiple sclerosis patients display deficient SHP-1 expression and enhanced inflammatory phenotype.

Authors:  George P Christophi; Michael Panos; Chad A Hudson; Rebecca L Christophi; Ross C Gruber; Akos T Mersich; Scott D Blystone; Burk Jubelt; Paul T Massa
Journal:  Lab Invest       Date:  2009-04-27       Impact factor: 5.662

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.